Eli Lilly (LLY) EBIT (2009 - 2026)

Eli Lilly (LLY) has reported EBIT for 18 consecutive years, with $9.5 billion the latest figure, recorded in Q1 2026.

• EBIT for Q1 2026 came in at $9.5 billion, up 80.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.4 billion (up 77.64% YoY), and the FY2025 annual result was $29.2 billion, up 80.56% from the prior year.
• EBIT was $9.5 billion for Q1 2026 at Eli Lilly, up from $8.9 billion in the prior quarter.
• Over five years, EBIT peaked at $9.5 billion in Q1 2026 and troughed at $1.6 billion in Q1 2023.
• Average EBIT over 5 years is $4.3 billion, with a median of $3.4 billion recorded in 2023.
• Year-over-year, EBIT sank 37.78% in 2023 and soared 101.07% in 2025.
• Over 5 years, EBIT stood at $2.1 billion in 2022, then soared by 44.94% to $3.0 billion in 2023, then jumped by 77.35% to $5.3 billion in 2024, then soared by 66.8% to $8.9 billion in 2025, then climbed by 6.69% to $9.5 billion in 2026.
• Per Business Quant data, the three most recent EBIT figures were $9.5 billion in Q1 2026, $8.9 billion in Q4 2025, and $8.0 billion in Q3 2025.